|
HS Code |
636342 |
| Chemical Formula | C4H2BrNO2S |
| Molar Mass | 222.03 g/mol |
| Appearance | Solid (usually a white - off - white powder) |
| Melting Point | Typically in a certain range (data may vary, around 160 - 180°C approximately) |
| Solubility In Water | Poorly soluble in water |
| Solubility In Organic Solvents | Soluble in some polar organic solvents like DMSO, DMF |
| Acidity | Carboxylic acid group makes it acidic, pKa value related to the carboxylic acid functionality (around 3 - 5 approximately) |
| Reactivity | Reactive at the carboxylic acid group (e.g., can form esters, amides) and at the bromine site (for substitution reactions) |
| Odor | Odorless or very faint odor |
As an accredited 2-Bromo-5-Thiazolecarboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of 2 - Bromo - 5 - Thiazolecarboxylic Acid packaged in airtight, resealable bags. |
| Shipping | 2 - Bromo - 5 - Thiazolecarboxylic Acid is shipped in accordance with strict chemical regulations. Packed in well - sealed, corrosion - resistant containers, it's transported by specialized carriers ensuring safe handling during transit to prevent any spillage or damage. |
| Storage | 2 - Bromo - 5 - Thiazolecarboxylic Acid should be stored in a cool, dry, well - ventilated area, away from sources of heat and ignition. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Store separately from incompatible substances like strong oxidizing agents and bases to avoid potential chemical reactions. |
What drives the choice of 2-bromo-5-thiazolecarboxylic acid in cGMP peptide coupling for constrained macrocycles?When a synthesis route demands a thiazole-5-carboxamide that can later undergo orthogonal C2 functionalization—particularly for constructing hepatitis C virus NS3/4A protease inhibitors—2-bromo-5-thiazolecarboxylic acid is often introduced at the tetrapeptide stage. The compound is incorporated at a stoichiometry of 1.00:1.03 (acid:amine component) using 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and N-methylmorpholine (NMM) in acetonitrile at 0–5 °C, a protocol that minimizes epimerization of the adjacent amino acid residue to <0.3% D-isomer as verified by chiral HPLC (Chiralpak IA, hexane/EtOH/TFA). Compliance is maintained under ICH Q11 Section 3.2 for starting material designation, with the supplier’s Drug Master File cross-referencing residual elemental impurities according to USP 〈232〉 and ICH Q3D. Following amide bond formation, the C2 bromine handle enables late-stage diversification: a copper(I)-mediated azide-alkyne cycloaddition (CuAAC) installs a triazole-bearing side chain in a flow chemistry setup using a Uniqsis FlowSyn reactor fitted with a 10 mL PTFE coil at 80 °C and 4 bar back-pressure regulation. The terminal product is a macrocyclic NS3/4A inhibitor of the paritaprevir structural class, where the thiazole ring contributes to optimal P2-binding pocket occupancy. Handling of the bulk intermediate in a Class 100,000 (ISO 8) cleanroom necessitates pre-dried excipients and <30% RH environment to avert hydrolytic debromination, a failure mode documented when H₂O content in the acetonitrile stream exceeds 0.02%.When Palladium-Catalyzed Amination Replaces Classical Nucleophilic Substitution in Kinase Inhibitor SynthesisIn the preparation of 2-anilino-thiazole-5-carboxamide pharmacophores for VEGFR-2 and PDGFR-β inhibitor candidates, 2-bromo-5-thiazolecarboxylic acid is first coupled with the appropriate aniline via Buchwald-Hartwig amination. The reaction is run in a 50 L Buchiglas reactor with a proprietary Pd-G3 dimer catalyst at 0.08 mol% loading and BrettPhos ligand in 2-methyltetrahydrofuran, with the acid pre-neutralized as its N,N-diisopropylethylammonium salt to prevent protonation of the active catalytic species. The molar ratio of bromoacid to 4-chloro-3-(trifluoromethyl)aniline is held at 1:1.02; exceeding 1.1 eq triggers palladium black aggregation, sharply reducing TON below 800. Subsequent amidation with the requisite 1,4-diaminocyclohexane core is carried out at 1.8 eq T3P (propylphosphonic anhydride) in ethyl acetate at 45 °C, a condition validated by Design of Experiments (DoE) to maintain residual 2-bromo impurity <0.15% in the final isolated product. The entire sequence is performed under ICH Q7 GMP for Phase II/III clinical supply, with an ICH Q3C-imposed limit of ≤500 ppm for 2-MeTHF in the final intermediate. The terminal pharmaceutical entity is an orally bioavailable kinase inhibitor—structurally related to the tivozanib class—where the 5-carboxamide linkage interacts with the hinge region of the ATP-binding site. Cleaning validation in multipurpose plant campaigns follows an HBEL-derived PDE value of 0.5 μg/cm² as per EMA/CHMP/CVMP/SWP/169430/2012, utilizing a total organic carbon (TOC) swab method with a quantification limit of 0.1 μg/cm².
Physical form specifications and supply-chain compliance matrix: a condensed audit reference
|
Competitive 2-Bromo-5-Thiazolecarboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The introduction of a halogen atom into the thiazole ring significantly modulates electronic distribution and cross-coupling reactivity. 2-Bromo-5-Thiazolecarboxylic Acid (CAS 120218-83-7, empirical formula C4H2BrNO2S, molecular weight 208.03 g·mol⁻¹) positions the bromine at C-2 and the carboxylic acid group at C-5. This regiochemical arrangement is distinct from its constitutional isomer, 5-Bromo-2-Thiazolecarboxylic Acid, where the functional group placement is reversed. The consequence is a difference in the preferred oxidative addition site during palladium-catalyzed transformations. In Suzuki-Miyaura couplings employing Pd(PPh₃)₄ or PdCl₂(dppf), the C-2 bromide of 2-Bromo-5-Thiazolecarboxylic Acid undergoes selective insertion, while the C-5 carboxylate remains available for amide bond formation or esterification without requiring protection-deprotection sequences. Batch records from kilo-scale production campaigns at ≥ 99.0% purity (HPLC, 254 nm) document a minimum anhydrous assay of 98.5% by non-aqueous titration, with residual palladium below 10 ppm as determined by ICP-MS.
Release criteria are aligned with pharmacopoeial expectations for late-stage intermediate vendors. Typical certificate-of-analysis parameters include appearance (off-white to pale yellow crystalline powder), identification by 1H NMR (400 MHz, DMSO-d₆) showing the aromatic singlet at δ 8.73 ± 0.05 ppm and the carboxylic proton exchangeable broad signal, and 13C NMR confirming the C-2 carbon with bromine at δ 136.2–136.8 ppm. HPLC purity is determined on a C18 column (150 × 4.6 mm, 5 µm) with a mobile phase of 0.1% trifluoroacetic acid in water/acetonitrile gradient; acceptance criterion is ≥ 99.0 area%. Water content by Karl Fischer coulometry is capped at ≤ 0.5%. Differential scanning calorimetry reveals a sharp endothermic melt at 171–174 °C (heating rate 10 °C/min, nitrogen purge). Any lot exhibiting a melt depression greater than 2 °C is quarantined for additional impurity profiling via LC-MS, as this often correlates with the presence of the des-bromo thiazole-5-carboxylic acid contaminant formed through reductive dehalogenation.
Coupling efficiency in a Pd₂(dba)₃/XPhos system is influenced by the halide’s crystal lattice water content. When the substance is stored at ambient relative humidity above 60%, a hygroscopic gain of 0.2–0.4 wt% occurs within 8 hours, leading to partial hydrolysis of the active palladium catalyst during scale-up. Process chemists on pilot-plant rigs equipped with jacketed 100 L glass-lined reactors routinely subject each drum to vacuum drying (40 °C, ≤ 10 mbar) for a minimum of 12 hours before charging. Failure to do so has been linked to a reduction in catalytic turnover number (TON) from a documented 1.2 × 10⁴ to below 4.0 × 10³, as measured by GC conversion of phenylboronic acid. A Karl Fischer check post-drying is mandatory under internal procedures derived from ICH Q7A guidelines for active pharmaceutical ingredient starting materials.
Amide bond formation using HATU or EDCI/HOBt proceeds without steric interference from the ortho-bromine. In a high-throughput parallel synthesis campaign across 24 amines, the mean isolated yield was 82%, with a relative standard deviation of 6.1%. The sole outlier—morpholine—gave 51% yield, attributed to competitive nucleophilic aromatic substitution at C-2 under prolonged heating (microwave irradiation, 120 °C, 30 min). This pathway is suppressed when coupling is performed at 0–5 °C with slow base addition (NMM, 1.05 eq). Distinguishing this product from 5-Bromo-2-Thiazolecarboxylic Acid, the latter exhibits a C-2 carboxyl group that undergoes decarboxylative cross-coupling under copper-silver co-catalysis, a reactivity mode not accessible to the 2-bromo-5-carboxy isomer due to the strong C-Br bond at the electron-deficient 2-position which resists protodecarboxylation conditions.
| Parameter | 2-Bromo-5-Thiazolecarboxylic Acid | 5-Bromo-2-Thiazolecarboxylic Acid | 2-Bromo-4-Thiazolecarboxylic Acid |
|---|---|---|---|
| Suzuki coupling (PhB(OH)₂, Pd(PPh₃)₄, K₂CO₃, dioxane/H₂O, 80 °C) | Complete conversion 15 min; isolated yield 93% | Complete conversion 25 min; isolated yield 88% | Complete conversion 45 min; side-product formation observed |
| Buchwald-Hartwig amination (morpholine, Pd₂(dba)₃, Xantphos, NaOtBu, toluene, 100 °C) | 78% yield, trace debromination | 64% yield, 8% debromination | No reaction; starting material recovered |
| Negishi coupling (4-MeC₆H₄ZnBr, PdCl₂(dppf), THF, rt) | 91% yield, < 2% homocoupled byproduct | 83% yield, 5% homocoupled byproduct | Not tested |
The presence of a free carboxylic acid at the 5-position while maintaining the bromide at 2-position is a differentiating attribute when compared with ester-protected analogs such as ethyl 2-bromothiazole-5-carboxylate. In multi-step routes to kinase inhibitors, chemists often require a late-stage amidation without preliminary saponification. The acid moiety of 2-Bromo-5-Thiazolecarboxylic Acid circumvents the use of LiOH or TMSOK, which can cleave labile functional groups elsewhere in the molecule. In a published route to a JAK2 inhibitor candidate (literature reference WO 2018/094395, example 47), 2-Bromo-5-Thiazolecarboxylic Acid was directly coupled to a chiral aminopiperidine under HATU conditions in DMF at 0 °C, yielding 71% after flash chromatography. The corresponding ester required a separate two-step sequence (hydrolysis then EDCI coupling) resulting in a combined yield of 62%. Storage of unreacted acid under inert atmosphere at 2–8 °C retained ≥ 99% purity after 18 months by HPLC, while the ester developed 2.3% of a transesterified impurity when stored in ethanol-containing solutions.
Metal content specifications differentiate the supply chain. A product labeled “pharma grade” is tested for 21 elemental impurities per USP ⟨232⟩ and ⟨233⟩. Typical results show cadmium < 0.1 ppm, lead < 0.5 ppm, arsenic < 0.2 ppm, mercury < 0.05 ppm, and cobalt < 0.3 ppm. The same substance sold as “research grade” may have up to 50 ppm of palladium carryover, which is incompatible with cGMP intermediate production when remaining steps are counted in the registered synthesis. This distinction is crucial for process R&D groups transitioning from medicinal chemistry (where residual metals may not be rigorously controlled) to Phase I manufacturing.
Differential scanning calorimetry-thermogravimetric analysis (DSC-TGA) coupled with evolved gas analysis identifies an exothermic decomposition onset at 205 °C with an energy release of −340 J/g. Accelerated rate calorimetry (ARC) in a 10 mL titanium bomb reveals an adiabatic temperature rise from 180 °C to 287 °C within 3.2 minutes, with a self-heat rate exceeding 50 °C/min above 220 °C. These data drive the recommendation that all drying operations remain below 60 °C, and short-path distillation, if ever attempted, must be avoided. Photolytic debromination has been monitored in methanol solution under ICH Q1B option 2 conditions: exposure to 1.2 million lux·hours of visible light and 200 watt·hours/m² of UV radiation resulted in 0.7% des-bromo impurity. Consequently, bulk solid is packaged in amber glass containers double-bagged under argon, and solution handling in amber volumetric flasks is standard.
| Test | Initial | 3 months | 6 months | Acceptance Criterion |
|---|---|---|---|---|
| Purity (HPLC area%) | 99.4% | 99.1% | 98.8% | ≥ 98.0% |
| Water content (% w/w) | 0.12% | 0.28% | 0.41% | ≤ 0.5% |
| Des-bromo impurity (% area) | 0.05% | 0.09% | 0.18% | ≤ 0.5% |
| Appearance | Off-white powder | No change | Slight yellowing | Pale yellow max |
Replacing the sulfur atom with oxygen (oxazole) or nitrogen (imidazole) alters the heterocycle’s electron-withdrawing capacity. The thiazole sulfur contributes to the ring current and decreases the pKa of the carboxylic acid to 2.9 ± 0.1 (calculated; experimental determination by potentiometric titration in 0.1 M NaClO₄ gave 2.85). The corresponding 2-bromo-5-oxazolecarboxylic acid exhibits a pKa of 2.4, which can lead to unintended decarboxylation at elevated temperatures in polar aprotic solvents. The imidazole analog is typically supplied as a hydrochloride salt due to basic N-3; the free base undergoes spontaneous dimerization. These differences manifest in downstream solubility during liquid-liquid extraction: at pH 4.5, the thiazole acid partitions with a log D of 0.9 (octanol/water), facilitating removal of neutral impurities by organic wash while retaining the product in aqueous phase as the carboxylate.
Material Safety Data Sheets filed under EC Regulation 1907/2006 (REACH) classify the solid as acute oral toxicity category 4 (H302), skin irritation category 2 (H315), and serious eye irritation category 2A (H319). Engineering controls on production floors include local exhaust ventilation (face velocity 100–150 ft/min) during powder charging into split-valve containment systems, with real-time particulate monitoring set to an occupational exposure limit of 0.1 mg/m³ as an 8-hour TWA for active pharmaceutical ingredients. These precautions are generic for halogenated aromatic compounds; nonetheless, the brominated thiazole specifically generates hydrogen bromide fumes upon combustion, requiring dry chemical or CO₂ extinguishers—never water jet—in storage facilities.
Shipping classification for 2-Bromo-5-Thiazolecarboxylic Acid falls under UN 3077 (Environmentally hazardous substance, solid, n.o.s.), packing group III, when shipped in 25 kg fiber drums with inner LDPE liners. This is juxtaposed against non-halogenated thiazole-5-carboxylic acid (not regulated for transport), a logistical nuance that procurement teams must factor into lead times for trans-Pacific shipments. Temperature-controlled air freight with phase-change material packs maintaining +2 °C to +8 °C is specified for shipments to tropical zones during April–October to prevent degradation that has been recorded in container shipment logs where internal temperatures exceeded 45 °C for 72 consecutive hours.
Customs harmonized tariff schedule classification remains 2934.10 (compounds containing an unfused thiazole ring in the structure). Import documentation requires a certificate of analysis not older than 12 months at the time of clearance, consistent with retest dating assigned under ICH Q1A(R2) for intermediates stored in the original sealed container.